TY - JOUR T1 - Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal JO - PharmacoEconomics UR - http://eprints.whiterose.ac.uk/141166/ PY - 2018/12/13 AU - Ren S AU - Squires H AU - Hock E AU - Kaltenthaler E AU - Rawdin A AU - Alifrangis C ED - DO - DOI: 10.1007/s40273-018-0750-2 Y2 - 2025/05/29 ER -